Calliditas Therapeutics AB - American Depositary Shares (CALT)

The company previously had an accelerated approval for its IgA nephropathy treatment.

CALT stock results show that Calliditas Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Suzhou MediLink partnered with Germany’s BioNTech to use MediLink’s TMALIN antibody-drug conjugate platform. MediLink will receive an upfront payment of $25 million and up to $1.8 billion in milestones, plus tiered royalties.

Asahi Kasei's $1.1 billion acquisition of Calliditas Therapeutics offers 208 SEK per share in cash. The deal boosts Asahi Kasei's global presence in immunology and renal disease markets, aligning with its strategic growth and expansion in the U.S. and Europe.

Pre-market stock movers are a hot topic as investors return to trading on Tuesday following the long holiday weekend!

CALT stock results show that Calliditas Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

U.S. stock futures were lower this morning, with the Dow futures trading lower by around 70 points on Wednesday.

Vera Therapeutics' significant market movements! Discover the latest on atacicept in IgA nephropathy trials, analyst ratings, and FDA approvals.

Shares of DouYu International Holdings Limited (NASDAQ: DOYU) rose sharply during Thursday’s session after announcing a share repurchase program.

U.S. stocks traded higher, with the Dow Jones index gaining around 80 points on Thursday. Shares of NeoGenomics, Inc. (NASDAQ: NEO) shares fell sharply during Thursday’s session after Natera won a preliminary injuction in a patent infringement lawsuit against NeoGenomics' RaDar test.

Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings.

The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) at 

U.S. stock futures were higher this morning, with the Dow Jones futures gaining more than 150 points on Thursday.